EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutatio...
Main Authors: | Roberto Chalela, Beatriz Bellosillo, Víctor Curull, Raquel Longarón, Sergi Pascual-Guardia, Diana Badenes-Bonet, Edurne Arriola, Albert Sánchez-Font, Lara Pijuan, Joaquim Gea |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/8/4/529 |
Similar Items
-
<i>KRAS</i> Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
by: Meichen Gu, et al.
Published: (2021-05-01) -
EGFR and KRAS mutation coexistence in lung adenocarcinomas
by: Vitor Manuel Leitão de Sousa, et al.
Published: (2015-04-01) -
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
by: Maria Colombino, et al.
Published: (2019-11-01) -
The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with <i>EGFR</i> Mutations
by: Chia-Yu Kuo, et al.
Published: (2019-10-01) -
<i>KRAS</i> and <i>BRAF</i> Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
by: Nuria Garcia-Carbonero, et al.
Published: (2020-01-01)